BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30580376)

  • 21. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
    Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
    Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lysine-specific histone demethylase 1 (LSD1): A potential molecular target for tumor therapy.
    Chen Y; Jie W; Yan W; Zhou K; Xiao Y
    Crit Rev Eukaryot Gene Expr; 2012; 22(1):53-9. PubMed ID: 22339659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of tissue factor pathway inhibitor-2 (TFPI-2) expression by lysine-specific demethylase 1 and 2 (LSD1 and LSD2).
    Mino K; Nishimura S; Ninomiya S; Tujii H; Matsumori Y; Tsuchida M; Hosoi M; Koseki K; Wada S; Hasegawa M; Sasaki R; Murakami-Yamaguchi Y; Narita H; Suzuki T; Miyata N; Mizukami T
    Biosci Biotechnol Biochem; 2014; 78(6):1010-7. PubMed ID: 25036127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models.
    Jasmine S; Mandl A; Krueger TEG; Dalrymple SL; Antony L; Dias J; Celatka CA; Tapper AE; Kleppe M; Kanayama M; Jing Y; Speranzini V; Wang YZ; Luo J; Trock BJ; Denmeade SR; Carducci MA; Mattevi A; Rienhoff HY; Isaacs JT; Brennen WN
    Prostate; 2024 Jul; 84(10):909-921. PubMed ID: 38619005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
    Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
    Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking.
    Li L; Li R; Wang Y
    Bioorg Med Chem Lett; 2019 Feb; 29(4):544-548. PubMed ID: 30611617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.
    Zheng YC; Ma J; Wang Z; Li J; Jiang B; Zhou W; Shi X; Wang X; Zhao W; Liu HM
    Med Res Rev; 2015 Sep; 35(5):1032-71. PubMed ID: 25990136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML.
    Vinyard ME; Su C; Siegenfeld AP; Waterbury AL; Freedy AM; Gosavi PM; Park Y; Kwan EE; Senzer BD; Doench JG; Bauer DE; Pinello L; Liau BB
    Nat Chem Biol; 2019 May; 15(5):529-539. PubMed ID: 30992567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
    Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
    Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug Design Concepts for LSD1-Selective Inhibitors.
    Ota Y; Suzuki T
    Chem Rec; 2018 Dec; 18(12):1782-1791. PubMed ID: 30277644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LSD1 in drug discovery: From biological function to clinical application.
    Liu HM; Zhou Y; Chen HX; Wu JW; Ji SK; Shen L; Wang SP; Liu HM; Liu Y; Dai XJ; Zheng YC
    Med Res Rev; 2024 Mar; 44(2):833-866. PubMed ID: 38014919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigating the Therapeutic Potential of LSD1 Enzyme Activity-Specific Inhibition by TAK-418 for Social and Memory Deficits in Rodent Disease Models.
    Baba R; Matsuda S; Maeda R; Murakami K; Yamamoto Y; Nakatani A; Kimura H
    ACS Chem Neurosci; 2022 Feb; 13(3):313-321. PubMed ID: 35061371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity.
    Schmitt ML; Hauser AT; Carlino L; Pippel M; Schulz-Fincke J; Metzger E; Willmann D; Yiu T; Barton M; Schüle R; Sippl W; Jung M
    J Med Chem; 2013 Sep; 56(18):7334-42. PubMed ID: 24007511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone H3 peptide based LSD1-selective inhibitors.
    Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T
    Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
    Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L
    J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
    Kakizawa T; Ota Y; Itoh Y; Suzuki T
    Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
    Barth J; Abou-El-Ardat K; Dalic D; Kurrle N; Maier AM; Mohr S; Schütte J; Vassen L; Greve G; Schulz-Fincke J; Schmitt M; Tosic M; Metzger E; Bug G; Khandanpour C; Wagner SA; Lübbert M; Jung M; Serve H; Schüle R; Berg T
    Leukemia; 2019 Jun; 33(6):1411-1426. PubMed ID: 30679800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors.
    Culhane JC; Wang D; Yen PM; Cole PA
    J Am Chem Soc; 2010 Mar; 132(9):3164-76. PubMed ID: 20148560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.
    Willmann D; Lim S; Wetzel S; Metzger E; Jandausch A; Wilk W; Jung M; Forne I; Imhof A; Janzer A; Kirfel J; Waldmann H; Schüle R; Buettner R
    Int J Cancer; 2012 Dec; 131(11):2704-9. PubMed ID: 22447389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A selective phenelzine analogue inhibitor of histone demethylase LSD1.
    Prusevich P; Kalin JH; Ming SA; Basso M; Givens J; Li X; Hu J; Taylor MS; Cieniewicz AM; Hsiao PY; Huang R; Roberson H; Adejola N; Avery LB; Casero RA; Taverna SD; Qian J; Tackett AJ; Ratan RR; McDonald OG; Feinberg AP; Cole PA
    ACS Chem Biol; 2014 Jun; 9(6):1284-93. PubMed ID: 24707965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.